| 2024-03-28 | -50.7% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$0.17 beats by $0.19 |
| 2024-03-28 | -50.7% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2024-08-23 | +43.9% | legal | SEC EDGAR | NDRA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-08-16 | -37.7% | news | Moomoo | ENDRA Life Sciences To Carry Out 1-for-50 Reverse Stock Split On August 20th, 2024 - Moomoo |
| 2026-03-25 | +33.9% | news | Business Wire | ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value |
| 2026-03-25 | +33.9% | news | Business Wire | ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value - Business Wire |
| 2026-03-25 | +33.9% | news | TipRanks | ENDRA Life Sciences Explores Strategic Alternatives Amid Restructuring - TipRanks |
| 2026-03-25 | +33.9% | expansion | Stock Titan | Strategic options review launched by ENDRA Life Sciences (Nasdaq: NDRA) - Stock Titan |
| 2024-08-21 | -32.1% | earnings | Seeking Alpha | Endra Life Sciences Q2 2024 Earnings Preview |
| 2024-03-29 | -30.3% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call Transcript |
| 2024-08-15 | -29.2% | earnings | InvestorPlace | NDRA Stock Earnings: ENDRA Life Sciences Misses EPS for Q2 2024 - InvestorPlace |
| 2024-06-06 | -27.2% | legal | SEC EDGAR | NDRA 8-K: 1.01, 7.01 (SEC Filing) |
| 2022-02-10 | -23.9% | legal | SEC EDGAR | NDRA 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-04-25 | +23.9% | news | Stock Titan | NDRA Stock Price, News & Analysis - Stock Titan |
| 2024-08-09 | -21.6% | legal | SEC EDGAR | NDRA 8-K: 5.02, 5.03, 5.07, 8.01 (SEC Filing) |
| 2024-11-15 | -20.3% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$9.54 |
| 2024-11-15 | -20.3% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2022-12-23 | -19.9% | legal | SEC EDGAR | NDRA 8-K: 5.02 (SEC Filing) |
| 2021-11-15 | -19.6% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2024-11-05 | -18.5% | news | Investing.com | ENDRA Life Sciences announces reverse stock split - Investing.com |
| 2024-08-28 | -16.9% | news | Seeking Alpha | ENDRA Life Sciences granted extension to regain compliance with Nasdaq continued listing requirements |
| 2024-08-28 | -16.9% | legal | SEC EDGAR | NDRA 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-08-15 | -13.6% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call Transcript |
| 2023-04-18 | -13.2% | legal | SEC EDGAR | NDRA 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-02 | +12.8% | legal | SEC EDGAR | NDRA 8-K: 1.01, 7.01 (SEC Filing) |
| 2022-12-05 | -11.9% | news | Seeking Alpha | ENDRA Life Sciences announces 1-for-20 reverse stock split |
| 2024-08-22 | -11.7% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript |
| 2024-08-22 | -11.7% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$0.08 misses by $0.01 |
| 2023-04-28 | +11.7% | news | Seeking Alpha | ENDRA Life Sciences prices stock and warrants offering |
| 2025-08-14 | +11.2% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$1.71 beats by $0.56 |
| 2023-08-14 | -10.9% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$0.43 |
| 2023-08-14 | -10.9% | legal | SEC EDGAR | NDRA 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-21 | -10.6% | news | Stock Titan | Equity shortfall puts ENDRA Life Sciences (NASDAQ: NDRA) at renewed Nasdaq delisting risk - Stock Titan |
| 2026-04-21 | -10.6% | news | TipRanks | ENDRA Life Sciences Faces Renewed Nasdaq Listing Compliance Risk - TipRanks |
| 2026-04-21 | -10.6% | news | Cổng thông tin điện tử Tỉnh Sơn La | ENDRA Life (NDRA) Stock: Price Action (Declines) 2026-04-20 - Downside Risk - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-02-26 | +10.0% | news | Business Wire | ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care |
| 2026-02-26 | +10.0% | news | Stock Titan | Device targets MRI-like liver fat tests for 2B MASLD patients - Stock Titan |
| 2025-12-15 | -9.8% | legal | SEC EDGAR | NDRA 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2025-11-13 | +8.7% | expansion | GuruFocus | ENDRA Life Sciences (NDRA) Launches HYPE Staking Initiative - GuruFocus |
| 2022-11-14 | -8.7% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Call Transcript |
| 2022-11-14 | -8.7% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2021-08-12 | -8.4% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2025-04-22 | +8.3% | news | Intellectia AI | NDRA Forecast — Price Prediction for 2026. Should I Buy NDRA? - Intellectia AI |
| 2022-03-30 | +7.8% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2024-04-19 | +7.3% | news | Seeking Alpha | ENDRA Life Sciences files to sell common stock, warrants |
| 2024-02-12 | -7.0% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2021-05-17 | +7.0% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | -7.0% | news | Zacks | NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision |
| 2023-05-15 | -6.8% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$0.93 beats by $0.11 |
| 2023-05-15 | -6.8% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2025-10-23 | -6.5% | legal | SEC EDGAR | NDRA 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-10-13 | +6.5% | news | Seeking Alpha | ENDRA Life Sciences announces at-market private placement of up to $14.4M |
| 2025-10-13 | +6.5% | news | Benzinga | Why Is ENDRA Life Sciences Stock Soaring Monday? - ENDRA Life Sciences (NASDAQ:NDRA) - Benzinga |
| 2025-10-13 | +6.5% | legal | Investing.com | ENDRA Life Sciences stock soars after securing $4.9M for crypto strategy - Investing.com |
| 2025-10-13 | +6.5% | expansion | Business Wire | ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca - Business Wire |
| 2025-10-13 | +6.5% | news | GuruFocus | ENDRA Life Sciences (NDRA) Announces $4.9M Private Placement - GuruFocus |
| 2022-08-15 | -6.0% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2023-07-06 | +5.9% | legal | SEC EDGAR | NDRA 8-K: 8.01 and (SEC Filing) |
| 2022-12-19 | +5.8% | legal | SEC EDGAR | NDRA 8-K: 1.01 and (SEC Filing) |
| 2023-05-16 | +5.7% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q1 2023 Earnings Call Transcript |
| 2022-04-21 | +5.7% | legal | SEC EDGAR | NDRA 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-10-30 | +5.6% | legal | SEC EDGAR | NDRA 8-K: 1.01 and (SEC Filing) |
| 2025-11-28 | -5.5% | legal | SEC EDGAR | NDRA 8-K: 5.02 and (SEC Filing) |
| 2021-06-15 | -5.4% | legal | SEC EDGAR | NDRA 8-K: 5.02 and (SEC Filing) |
| 2023-03-14 | -5.0% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q4 2022 Earnings Call Transcript |
| 2023-03-14 | -5.0% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of $1.04 beats by $1.94 |
| 2023-03-14 | -5.0% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2025-11-14 | -4.7% | legal | SEC EDGAR | NDRA 8-K: 8.01 (SEC Filing) |
| 2025-07-09 | -4.5% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2022-08-07 | +4.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for ENDRA Life Sciences (NDRA) - Zacks Investment Research |
| 2026-03-31 | -4.3% | news | Business Wire | ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-31 | -4.3% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$8.93 misses by $2.34 |
| 2026-03-31 | -4.3% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | -4.3% | analyst | Stock Titan | ENDRA Life Sciences (NASDAQ: NDRA) cuts 2025 operating costs sharply - Stock Titan |
| 2025-03-31 | -4.2% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$56.94 |
| 2025-03-31 | -4.2% | legal | SEC EDGAR | NDRA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-05-10 | -4.1% | legal | SEC EDGAR | NDRA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-11-22 | +4.1% | news | Seeking Alpha | ENDRA Life Sciences regains compliance with Nasdaqs listing rule |
| 2024-11-22 | +4.1% | legal | SEC EDGAR | NDRA 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-08-18 | -4.0% | earnings | Quiver Quantitative | ENDRA LIFE SCIENCES Earnings Preview: Recent $NDRA Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative |
| 2026-04-22 | -3.9% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | ENDRA Life (NDRA) Stock Chart | Q4 2025: Earnings Fall Short - Free Cash Margin - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2024-05-15 | -3.8% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q1 2024 Earnings Call Transcript |
| 2024-08-13 | -3.8% | executive | Seeking Alpha | ENDRA Life Sciences appoints Alexander Tokman as acting CEO |
| 2024-08-13 | -3.8% | legal | SEC EDGAR | NDRA 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-08 | -3.7% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is ENDRA Life (NDRA) Stock Near Resistance | Price at $5.10, Down 4.49% - Trending Entry Points - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-10 | -3.2% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is ENDRA Life (NDRA) Stock Good for Portfolio | Price at $4.95, Down 6.78% - High Volume Stocks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2024-02-14 | +3.0% | legal | Seeking Alpha | Endra Life Sciences files for $50M mixed securities shelf |
| 2021-06-21 | -2.9% | legal | SEC EDGAR | NDRA 8-K: 1.01, 1.02 (SEC Filing) |
| 2022-11-02 | -2.6% | analyst | TradingView | NDRA Forecast — Price Target — Prediction for 2027 - TradingView |
| 2022-05-12 | +2.5% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2026-02-17 | -2.4% | news | FinancialContent | 5 Stocks Under $5 to Watch Now: OBAI, NDRA, RIME, VTIX, OPEN - FinancialContent |
| 2024-01-24 | +2.3% | earnings | TradingView | ENDRA Life Sciences Inc. Earnings and Revenue – NASDAQ:NDRA - TradingView |
| 2025-01-28 | +2.2% | news | Yahoo Finance | What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock - Yahoo Finance |
| 2025-05-15 | +2.1% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$1.86 |
| 2025-05-15 | +2.1% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2024-10-29 | +1.9% | legal | SEC EDGAR | NDRA 8-K: 5.07 and 8.01 (SEC Filing) |
| 2023-11-15 | +1.8% | earnings | Seeking Alpha | ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript |
| 2024-05-14 | -1.7% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$0.26 beats by $0.01 |
| 2024-05-14 | -1.7% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2024-05-14 | -1.7% | earnings | MarketBeat | ENDRA Life Sciences (NDRA) Stock Forecast and Price Target 2026 - MarketBeat |
| 2024-05-20 | -1.7% | legal | SEC EDGAR | NDRA 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-11-17 | +1.6% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$2.10 misses by $0.15 |
| 2025-11-17 | +1.6% | news | Business Wire | ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results - Business Wire |
| 2022-12-02 | -1.4% | legal | SEC EDGAR | NDRA 8-K: 5.07 and 8.01 (SEC Filing) |
| 2023-11-14 | +1.4% | earnings | Seeking Alpha | Endra Life Sciences GAAP EPS of -$0.40 beats by $0.03 |
| 2023-11-14 | +1.4% | legal | SEC EDGAR | NDRA 8-K: 2.02 and (SEC Filing) |
| 2023-07-25 | -1.1% | legal | SEC EDGAR | NDRA 8-K: 8.01 (SEC Filing) |
| 2021-04-27 | +0.4% | legal | SEC EDGAR | NDRA 8-K: 2.02 and 8.01 (SEC Filing) |
| 2025-10-15 | +0.4% | legal | SEC EDGAR | NDRA 8-K: 1.01, 1.02, 3.02, 5.08, 7.01, 8.01 (SEC Filing) |
| 2025-12-04 | -0.2% | news | Investing.com | ENDRA Life Sciences stock falls after liver device study results - Investing.com |
| 2025-07-23 | +0.2% | legal | SEC EDGAR | NDRA 8-K: 8.01 (SEC Filing) |
| 2026-03-18 | -0.2% | news | marketscreener.com | ENDRA Life Sciences (NASDAQ: NDRA) - marketscreener.com |
| 2026-04-25 | — | news | FinancialContent | Press Releases about Battalion Oil Corporation Common Stock (NYSE:BATL) - FinancialContent |
| 2026-04-24 | — | analyst | MSN | ENDRA Life Sciences (NDRA) price target decreased by 10.00% to 27.54 - MSN |